Catalyst Pharmaceuticals Inc (CPRX)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 387,881 | 300,421 | 206,831 | 169,598 | 87,630 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $387,881K
= 0.00
The debt-to-equity ratio of Catalyst Pharmaceuticals Inc has consistently been 0.00 for the past five years, including as of December 31, 2023. This indicates that the company has not utilized any debt financing to fund its operations and growth, relying solely on equity to finance its activities. A debt-to-equity ratio of 0.00 suggests that the company is not burdened by debt obligations and has a strong equity base. While a low debt-to-equity ratio is typically considered favorable as it signifies lower financial risk, it is important to note that having some level of debt can also be advantageous for leveraging growth opportunities. Overall, Catalyst Pharmaceuticals Inc's consistent 0.00 debt-to-equity ratio signals a conservative financial approach with minimal reliance on debt financing.
Peer comparison
Dec 31, 2023